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Abstract
Background: ω-3 Fatty acid (FA)–containing parenteral nutrition (PN) is associated with improvements in patient outcomes and
with reductions in hospital length of stay (HLOS) vs standard PN regimens (containing non–ω-3 FA lipid emulsions). We present a
cost-effectiveness analysis of ω-3 FA–containing PN vs standard PN in 5 European countries (France, Germany, Italy, Spain, UK)
and the US. Methods: This pharmacoeconomic model was based on estimates of ω-3 efficacy reported in a recent meta-analysis
and data from country-specific sources. It utilized a probabilistic discrete event simulation model to compare ω-3 FA–containing
PN with standard PN in a population of critically ill and general ward patients. The influence of model parameters was evaluated
using probabilistic and deterministic sensitivity analyses. Results: Overall costs were reduced with ω-3 FA–containing PN in all 6
countries compared with standard PN, ranging from €1741 (±€1284) in Italy to €5576 (±€4193) in the US. Expenses for infections
and HLOS were lower in all countries for ω-3 FA–containing PN vs standard PN, with the largest cost differences for both in the
US (infection: €825 ± €4001; HLOS: €4879 ± €1208) and the smallest savings in the UK for infections and in Spain for HLOS
(€63 ± €426 and €1636 ± €372, respectively). Conclusion: This cost-effectiveness analysis in 6 countries demonstrates that the
superior clinical efficacy of ω-3 FA–containing PN translates into significant decreases in mean treatment cost, rendering it an
attractive cost-saving alternative to standard PN across different healthcare systems. (JPEN J Parenter Enteral Nutr. 2021;45:999–
1008)
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Clinical relevancy statement
A recent meta-analysis showed that ω-3 fatty acid (FA)–
containing parenteral nutrition (PN) is associated with
statistically and clinically significant reductions in the rates
of infection and sepsis as well as in the duration of
hospitalization and length of stay in the intensive care
unit. This cost-effectiveness analysis for 6 countries (France,
Germany, Italy, Spain, UK, and US) demonstrates that
these outcomes translate into significant decreases in mean
hospital costs with ω-3 FA–containing PN in comparison
with PN not containing ω-3 FAs.
Background
Hospitalized critically ill and surgical patients typically
receive parenteral nutrition (PN) if oral or enteral nutrition
is contraindicated or insufficient. A complete all-in-one
PN admixture comprises amino acids/protein, glucose, elec-
trolytes (depending on patient condition), lipid, micronu-
trients (such as vitamins), and trace elements to sustain
or improve patient nutrition status and clinical outcomes.
Lipid is an integral part of PN, as it is a dense source of
energy and supplies the building blocks for cell membranes
and essential fatty acids (FAs) in PN to prevent deficiencies.1
Traditionally, the lipid added to PN in the form of a
lipid emulsion was derived from soybean oil.2 Soybean oil
emulsions, however, contain high concentrations of linoleic
acid and other ω-6 polyunsaturated FAs, which may have
detrimental properties.1 Following concerns that ω-6 FA
may promote inflammation and immunosuppression, lipid
emulsions with balanced mixtures of different oil sources,
such as soybean oil, medium-chain triglycerides, olive oil,
and fish oil, were developed for use in PN.1 There is a
strong body of evidence that ω-3 FAs derived from fish
oil, especially eicosapentaenoic acid, docosahexaenoic acid,
and their respective metabolites, possess beneficial anti-
inflammatory and immunomodulatory properties and play
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a key role in the resolution of inflammation across a wide
range of patient groups, including surgical, critically ill,
and cancer groups.1,3 This attenuation of proinflammatory
processes could contribute to the trend observed across
several studies and meta-analyses that report decreases in
hospital and intensive care unit (ICU) length of stay (LOS)
when using PN regimens containing ω-3 FA–containing
lipid emulsions.4-10
In general, decreases in hospital LOS (HLOS) are associ-
ated with a lower risk of infection,11 and a shorter ICULOS
reduces general deconditioning due to prolonged bed rest,
sedation, and immobilization, with overall improvements
in patient quality of life.12 A number of clinical trials
and meta-analyses in hospitalized patients demonstrated
that PN containing ω-3 FA is associated with better clin-
ical outcomes than standard PN regimens (PN with lipid
emulsions not containing ω-3 FA; ie, derived from sources
such as soybean oil and/or olive oil), including decreases in
morbidity and mortality,6,13 shortened HLOS4-9,14 and ICU
LOS,15 and reduced infection rates.4,5,8,9
In a previously published clinical meta-analysis and sub-
sequent pharmacoeconomic analysis, ω-3 FA–containing
PN was shown to be more clinically effective and more
cost-effective than standard PN in both ICU and non-
ICU patients.16,17 Based on Italian outcome data, this
pharmacoeconomic analysis modeled the cost-effectiveness
of PN with and without ω-3 FA in 4 countries (France,
Germany, Italy, UK) and found that infection rates, overall
LOS, and total cost per patient were reduced with the use
of ω-3 FA–containing PN. The higher treatment costs for
ω-3 FA–containing PN were completely offset by the lower
overall costs, demonstrating that PN containing ω-3 FAwas
cost-effective in French,German, Italian, andUKhospitals.
A more recent meta-analysis,4 which included 49 ran-
domized controlled trials and a total of 3641 patients, re-
ported a significantly lower relative risk of infection (40%),
a 56% reduced risk of sepsis, and a nonsignificant 16% re-
duction inmortality in patients receiving PN containingω-3
FA compared with standard PN. In addition to decreases
in mean length of ICU and hospital stays, the analysis
also showed significant reductions in the relative risk of
infection and sepsis.4 Whereas the positive clinical effects of
ω-3 FA–containing PN found in a previous analysis17 were
confirmed in the recent analysis adhering to current study
quality standards, the evaluation of the economic impact
of ω-3 FA–containing PN remains to be updated.
The aim of the present study was to investigate the
cost-effectiveness of ω-3 FA–containing PN compared with
standard PN without fish oil based on a recent meta-
analysis.4 Here, we present the results of 6 country-specific
cost-effectiveness models comparing the utilization of ω-3
FA–containing PN with standard PN from the perspective
of a hospital in France, Germany, Italy, Spain, the UK, and
the US.
Methods
This analysis modeled the cost-effectiveness of ω-3 FA–
containing and standard PN based on country-specific data
sources for 6 countries (France, Germany, Italy, Spain, UK,
and the US).
Model Structure
Six separate cost-effectiveness models comparing ω-3 FA–
containing PNwith standard PNwithout fish oil were devel-
oped and simulated for hospitals in France, Germany, Italy,
Spain, the UK, and the US. Overall, the model generation
included the following steps: (1) conceptualization of a
logical structure for both patient cohorts (critically ill cohort
[CR] and acute general ward cohort [GE]); (2) identification
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Figure 1. Simplified model structure including 2 treatment arms, each with critically ill and acute general ward patients. FA, fatty
acid; PN, parenteral nutrition.
of country-specific clinical outcomes for patients receiving
standard PN in both cohorts; (3) identification of country-
specific sources for drug acquisition and hospital service
costs; (4) simulation of country-specific clinical outcomes
for patients receiving ω-3 FA–containing PN by applying
the ω-3 efficacy estimates from the recent meta-analysis to
(2); (5) calculation of the country-specific total cost per sim-
ulated patient; (6) analysis of the result’s sensitivity to input
parameter uncertainty via deterministic and probabilistic
sensitivity analyses (PSAs).
The models were based on a probabilistic discrete event
simulation technique and developed in Excel (Microsoft
Corporation, Redmond, WA, USA). Simulations were run
over 10,000 iterations, with each iteration representing 1
patient.
Patient Population and Epidemiological Data
On the patient level, all models included 2 treatment arms
(ω-3 FA–containing PN and standard PN)with each patient
passing simultaneously through both arms, thus enabling
both alternative simulations to run on the same cohort
(Figure 1). The simulated hospitalized patients were sent to
CR andGEpathways and could receive either PN treatment
option (ω-3 FA–containing PN or standard PN). In the
present pharmacoeconomic analysis, patients from both
settings (CR and GE) were combined to evaluate the cost-
effectiveness of ω-3 FA–containing PN in a mixed adult
population of CR and GE patients.
Model Inputs and Data Sources
Relative treatment effects for patients receiving ω-3 FA–
containing PN were derived from a recent meta-analysis.4
Economic data such as daily costs, costs per infection,
and costs for PN treatment were extracted from published
sources for each country and treatment arm (Table 1).4,18-47
The models also included inputs on the clinical outcomes
nosocomial infections, HLOS, and mortality. The latter
2 parameters defined the end of the patient pathway,
whereas the first reflected only costs. Mean HLOS and
mean incidence of infection with ω-3 FA–containing PN
and standard PN without ω-3 FA varied widely between
countries (Table 2), with the shortest mean HLOS and the
lowest incidence of infection for both treatment groups
in the US and Germany, respectively. For inclusion of
time-to-event parameters, such as HLOS, in the model, a
Weibull distribution fitting was performed, with population
parameters estimated using the method of moments.
For the 5 European countries, the daily costs of PN
were estimated based on current market shares, the daily
number of PN bags per patient, and current market prices.
For the estimation of daily costs in the US, a model was
created to approximate daily lipid requirements based on
patient age distribution43 and patient weight in gender-
and age-specific groups.48 The cost of lipid emulsions was
based on the lowest cost for standard PN while using the
manufacturer price for ω-3 FA–containing PN, thus leading
to a conservative estimate of the latter. Costs were modeled
according to local currencies in each country but converted
into euros (EUR) to facilitate comparability. Pound sterling
(GBP) and US dollar (USD) were converted to EUR using
the mean exchange rates for January 2020: GBP-EUR:
1.1759; USD-EUR: 0.9005. Exchange rates were derived
from https://www.oanda.com/. No discount rate was ap-
plied to the costs, because of the short time frame of the
simulation.
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Table 1. Country- and Patient Cohort–Specific Model Inputs, Including Clinical and Economic Data As Well As Overall Efficacy
Estimates and Their Respective Sources.




CR patients, % 454
GE patients, % 554
Clinical input parameters
Mean HLOS; CR, d 31.2 ± 18.518 29.1 ± 18.722 36.8 ± 28.527 45.9 ± 23.935 19.65 ± 19.339 20.1 ± 15.543
Mean HLOS ± SD; GE, d 23.6 ± 16.019 15.2 ± 9.723 29.75 ± 19.028 33.6 ± 26.736 29.75 ± 19.028 14.3 ± 16.344,b
Infection; CR, % 4718 1824 4529 4635 1939 3443
Infection; GE, % 4219 1223 2730 1936 1540 2744,
b
Mean PN duration ± SD, CR, d 14 ± 818 8 ± 822 7 ± 631 19 ± 1535 9 ± 539 7 ± 743
Mean PN duration ± SD, GE, d 14 ± 1419 8 ± 523 15 ± 1028 13 ± 1136 15 ± 1028 6 ± 444, b
Mortality, CR, % 2818 1922 1527 4635 3639 2143
Mortality, GE, % 319 923 1130 2936 3040 1144,
b
Economic input parameters
Mean cost, CR/d, € ($) 1136 (1262)20 1556 (1728)25 1108 (1230)32 981 (1089)37 1912 (2123)41 2914 (3236)43
Mean cost, GE/d, €($) 785 (872)20 581(645)25 654 (726)33 610 (677)37 962 (1068)41 1777(1973)45
Mean cost of infection, € ($) 1162 (1290)21 2006 (2228)26 1855 (2060)34 2085 (2315)38 872 (968)42 6641 (7375)46
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ω-3 FA–containing PN efficacy,
mean ± SD
HLOS mean difference, d Infection relative risk
−2.14 ± 0.544 0.60 ± 0.064
CR, critically ill cohort; FA, fatty acid; GE, acute general ward cohort; HLOS, hospital length of stay; PN, parenteral nutrition; SD, standard
deviation.
aPound sterling (GBP) and US dollar (USD) converted to euro (EUR) using the average exchange rates of January 2020: GBP-EUR: 1.1759,
USD-EUR: 0.9005.
bData combined from 2 groups according to the Cochrane handbook.47
cSee methods section for basis of calculations; Fresenius Kabi data on file.
Table 2. Country-Specific Efficacy Estimates: HLOS and








France ω-3 FA–containing PN 25.2 26
Standard PN 27.3 44
Germany ω-3 FA–containing PN 20.4 9
Standard PN 22.6 15
Italy ω-3 FA–containing PN 31.2 21
Standard PN 33.3 35
Spain ω-3 FA–containing PN 37.3 19
Standard PN 39.5 35
UK ω-3 FA–containing PN 23.1 10
Standard PN 25.2 16
US ω-3 FA–containing PN 14.9 18
Standard PN 17.1 31
FA, fatty acid; HLOS, hospital length of stay; PN, parenteral
nutrition.
Sensitivity Analysis
The influence of model parameters on calculated estimates
was evaluated using probabilistic and deterministic sensitiv-
ity approaches.
In the PSA, 1000 sets of unique parameter combinations
are created, drawing each model parameter within the
extremes of its probability distribution. In case of missing
data on uncertainty, a 20% standard deviation of the mean
value was used and an appropriate probability distribution
according to the shape of the data was chosen.
In the deterministic sensitivity analyses, simulations were
repeated with variations of parameter values to the lower
and upper confidence interval limits, while keeping the
remaining parameter values constant.
Results
Costs in the 6 Countries Analyzed
A recent meta-analysis4 showed that PN containing ω-3
FA was associated with a significant increase in clinical
effectiveness: Mean HLOS was reduced by 2.14 ± 0.54 days
and the relative risk of infection was 0.60 ± 0.06 with ω-3
FA–containing PN vs standard PN (Table 1). This increase
in clinical effectiveness with ω-3 FA–containing PN leads
to a significant decrease in mean cost per adult patient in
all of the European and US hospital settings investigated.
Total costs were reduced in all 6 countries and amounted
to €2244 ± €848 ($2492 ± $942) in France, €2228 ± €1389
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($2474 ± $1542) in Germany, €1741± €1284 in Italy ($1933
± $1426), €1782 ± €1307 ($1979 ± $1451) in Spain, €2973
± €1108 (£2528 ± £942 or $3300 ± $1230) in the UK, and
€5576 ± €4193 ($6192 ± $4657) in the US. Expenses for
infections and HLOS were lower in all 6 countries for ω-3
FA–containing PN compared with standard PN, with the
US accruing the largest savings for both (infection: €825
± €4001 [$916 ± $4443]; HLOS: €4879 ± €1208 [$5418 ±
1342]). The lowest cost differences were observed in the UK
for infection (€63 ± €426 [£54 ± £362, $70 ± $473]) and in
Spain for HLOS (€1636 ± €372 [$1817 ± $413]). Detailed
results regarding the cost of PN, infections,HLOS, and total
costs are reported in Table 3.
In summary, ω-3 FA–containing PN demonstrated supe-
rior efficacy with a concurrent overall cost reduction in all
countries compared with standard PN without ω-3 FA via
reductions in mean length of ICU and hospital stays, as well
as lower incidences of infection and sepsis.
Sensitivity Analyses
Sensitivity analyses demonstrated the stability and robust-
ness of the outcomes in this pharmacoeconomic assess-
ment to parameter changes. For all 6 countries, ω-3 FA–
containing PN was associated with cost savings compared
with standard PN in 100% of the simulations. Our analyses
showed that in order to achieve an average cost saving
of €0 with ω-3 FA–containing PN per treated patient
compared with standard PN, the daily cost of ω-3 FA–
containing PN would have to be equal to €224.77 ($ 249.61)
in France, €476.99 ($ 529.69) inGermany, €438.70 ($ 487.17)
in Italy, €145.96 ($ 162.09) in Spain, €492.98 (£419.23, $
547.45) in the UK, and €974.48 ($1082.2) in the US. The
incremental cost-effectiveness ratio (ICER) plots in Figure 2
display the results of 1000 ICER estimates and thus the
cost required to avoid 1 case of infection using the most
effective strategy. For all 6 countries, the incremental costs
for avoided infections were negative, including the entirety
of the 95% confidence interval ellipses. Hence, each avoided
infection with ω-3 FA–containing PN was associated with a
reduction in total cost, which is referred to as dominance in
pharmacoeconomic terms (ie, better clinical outcomes at a
lower cost).
The results of the deterministic sensitivity analyses are
displayed as tornado diagrams, which show the influence
of variations in key parameters on cost savings per patient
(Figure 3). These graphs indicate that for both treatment
options (ω-3 FA–containing PN and standard PN), the
most influential parameter for cost savings across all 6
countries was mean difference of HLOS (topmost bars). In
France, Germany, the UK, and the US, the second most
influential factor was the cost of caring for critically ill
patients, whereas in Italy and Spain the cost of ω-3 FA–
containing PN was ranked second.
On average, the use of ω-3 FA–containing PN was
demonstrated to be a cost-saving strategy under the circum-
stances and conditions of the model.
Discussion
According to the US guidelines on the provision and
assessment of nutrition support therapy in adult critically
ill patients, PN has evolved from mere nutrition support to
nutrition therapy.49 Adequately fed patients are thought to
benefit from improvements in a range of clinical factors,
such as attenuation of the metabolic response to stress,
prevention of oxidative cellular injury, and favorable mod-
ulation of immune responses.49 ω-3 FA–containing PN in
particular has been associated with significantly improved
patient outcomes4-9,13,14,50 and, as shown in the present
pharmacoeconomic analysis, concurrent cost savings.
This cost-effectiveness analysis builds on a previously
published model16 but includes a wider country scope,
country-specific analyses, and a more sophisticated source
selection. Using a robust model and country-specific data
from 6 countries (France, Germany, Italy, Spain, UK, US),
we demonstrate that PN containing ω-3 FA is, with very
great likelihood, a dominant alternative to standard PN for
a mixed population of CR and GE patients in terms of
treatment cost. Despite the higher acquisition cost of ω-
3 FA–containing PN in comparison with standard PN in
nearly all of the countries analyzed, the superior efficacy
with regard to patient outcomes renders it a cost-saving
alternative to standard PN.
Since economic models are built on data from various
sources with the objective of creating an accurate cost
estimate, their results are limited by the availability of valid
data inputs and the overall assumptions upon which the
models are built. The limitations of the presented models
are mainly centered around input data sources. Although
some data were available, more research evaluating clinical
outcomes, particularly in CR patients, would be indicated.
The literature, at least for some countries, was incomplete
(none for GE patients in the UK) and, in part, outdated.
Specifically, some of the data sources for CR patients in
France, Germany, Italy, and Spain were more than a decade
old.
Accurate economic inputs are just as important as clini-
cal information to achieve accurate cost estimates. Updated
and valid sources for hospital cost data are not easily
available, especially at the desired level of detail in the
breakdown by components. Some data elaboration and
assumptions were necessary also in this study; nevertheless,
we are confident in themain conclusions, for 2main reasons.
Firstly, when there was the need for an assumption, we have
always adopted the most conservative. Secondly, sensitivity
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Figure 2. Scatterplots of 1000 incremental cost-effectiveness ratio estimates in PSAs for all 6 countries. CI, confidence interval;
PSA, probabilistic sensitivity analysis.
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Figure 3. Country-specific tornado plots representing the sensitivity of savings with ω-3 FA–containing PN to a variation in key
parameters (parameters ranked by degree of influence). CR, critically ill cohort; FA, fatty acid; GE, acute general ward cohort;
HLOS, hospital length of stay; O-3, ω-3; PN, parenteral nutrition; Prob from H, probability to be discharged alive from the
general and/or critical care pathways.
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This model, in conjunction with a recently published
meta-analysis,4 has shown that ω-3 FA–containing PN is
beneficial for patients in terms of improved clinical out-
comes as well as for healthcare systems because of lower
overall costs. The higher acquisition cost for ω-3 FA–
containing PN compared with standard PN is offset by
cost reductions due to shorter HLOS and fewer infections,
demonstrating that not only acquisition costs but overall
treatment costs should influence the choice of treatment op-
tion. We would like to place particular emphasis on the fact
that clinical interventions that improve patient outcomes
while providing saving costs are very rare and support the
use of ω-3 FA–containing PN in appropriate settings.
The accumulating evidence regarding the improve-
ment of clinical outcomes with ω-3 FA–containing PN
in comparison with standard PN in adult hospitalized
patients4-9,13,14,50 may contribute to evidence-based treat-
ment decisions and future guideline development. Concur-
rent cost savings with PN containing ω-3 FA, as shown in
this cost-effectiveness analysis, may provide an additional
benefit in this regard.
In summary, we demonstrate that ω-3 FA–containing
PN is likely a dominant alternative to standard PN from
a hospital point of view, with a decrease in mean costs for
all 6 countries evaluated (France, Germany, Italy, Spain,
UK, US). With regard to the positive clinical and economic
outcomes demonstrated in the present analysis and in the
recent meta-analysis4 on which this pharmacoeconomic
evaluation is built, we suggest that ω-3 FA–containing PN
be considered as standard of care and suggest using the
present publication and that by Pradelli et al4 as a reference
for guideline recommendations.
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